Could HIF-1α be a novel biomarker for the clinical course and treatment of pulmonary embolism?

Kerget B., Afşin D., Aksakal A., Aksakal A., Aşkin S., Araz Ö.

Turkish journal of medical sciences, cilt.50, sa.4, ss.963-968, 2020 (SCI-Expanded) identifier identifier identifier

  • Yayın Türü: Makale / Tam Makale
  • Cilt numarası: 50 Sayı: 4
  • Basım Tarihi: 2020
  • Doi Numarası: 10.3906/sag-1908-93
  • Dergi Adı: Turkish journal of medical sciences
  • Derginin Tarandığı İndeksler: Science Citation Index Expanded (SCI-EXPANDED), Scopus, Academic Search Premier, CAB Abstracts, EMBASE, MEDLINE, Veterinary Science Database, TR DİZİN (ULAKBİM)
  • Sayfa Sayıları: ss.963-968
  • Anahtar Kelimeler: HIF-1 alpha, pulmonary thromboembolism, hypoxia, ENDOTHELIAL GROWTH-FACTOR, VEGF, THROMBOSIS
  • Atatürk Üniversitesi Adresli: Evet

Özet

Background/aim: Pulmonary embolism (PE) is associated with high morbidity and mortality rates if not diagnosed and treated rapidly. The aim of our study was to investigate the relationship between levels of hypoxia-induced factor-1 alpha (HIF-1 alpha) and clinical course and prognosis in patients with intermediate low-risk, intermediate high-risk, and high-risk PE.